The groundbreaking rise of copyright’s flagship product presented a massive prospect for shareholders , but its patent has ended, creating a challenging landscape. Generic versions have entered the space , eroding sales and putting a strain on profit yields. While established click here pharmaceutical companies continue a presence in this field ,